Abstract
We present a very interesting case of lung adenocarcinoma carrying an uncommon EGFR exon 19 insertion with concomitant PIK3CA mutation showing dramatic and persisting improvement upon erlotinib therapy, after progression during PI3K inhibitor.
Keywords:
EGFR; Erlotinib; Gene mutations; NSCLC; PI3K inhibitor; PI3KCA.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
MeSH terms
-
Adenocarcinoma / diagnosis
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / genetics*
-
Adenocarcinoma / mortality
-
Adenocarcinoma of Lung
-
Adult
-
Antineoplastic Agents / therapeutic use*
-
DNA Mutational Analysis
-
ErbB Receptors / genetics*
-
Female
-
Humans
-
Immunohistochemistry
-
Lung Neoplasms / diagnosis
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics*
-
Lung Neoplasms / mortality
-
Mutation*
-
Nuclear Proteins / genetics*
-
Protein Kinase Inhibitors / therapeutic use*
-
Tomography, X-Ray Computed
-
Transcription Factors / genetics*
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Nuclear Proteins
-
PI3KCA protein, human
-
Protein Kinase Inhibitors
-
Transcription Factors
-
ErbB Receptors